Literature DB >> 16276190

Cannabinoid antagonist AM 281 reduces mortality rate and neurologic dysfunction after cecal ligation and puncture in rats.

Yuji Kadoi1, Hiroshi Hinohara, Fumio Kunimoto, Shigeru Saito, Fumio Goto.   

Abstract

OBJECTIVES: The purpose of this study was to examine whether anandamide, an endogenous cannabinoid receptor ligand, is involved in the pathogenesis of septic encephalopathy.
DESIGN: Prospective, controlled study.
SUBJECTS: Male Wistar rats (7 wks old) were randomly divided into four groups as follows: group 1, control (0.5 mL of saline injected subcutaneously); group 2, sham (surgical abdominal incision and suturing were performed, but ligation and puncture of the cecum were omitted); group 3, cecal ligation and puncture (CLP); group 4, CLP + AM 281 ([N-morpholin-4-yl]-5-[2,4-yl]-5-[2,4-dichlorophenyl]-4-methyl-1H-pyrazole-3-carboxamide) as the cannabinoid receptor antagonist (1 mg/kg intraperitoneally).
INTERVENTIONS: Sepsis was induced by CLP under pentobarbital anesthesia (10 mg/kg intraperitoneally) with 1% isoflurane. A 2-Fr high-fidelity micromanometer catheter was inserted into the left ventricle via the right carotid artery to assess hemodynamics. Each of the rats was neurologically assessed at 30 mins and 12, 24, and 48 hrs after the treatment. The cytoplasmic levels of caspase-3 in the hippocampi were assayed before surgery and at 30 mins and 24 and 48 hrs after surgery using Western blotting techniques. To examine the effects of AM 281 on neurologic function and mortality rate, we set another control group treated solely with AM 281. Selective inducible nitric oxide synthase inhibitor, L-N6-(1-iminoethyl)-lysine (4 mg/kg), was injected intraperitoneally immediately after CLP to produce the CLP + L-N6-(1-iminoethyl)-lysine group to exclude the influence of depressed hemodynamics on neurologic impairment.
MEASUREMENTS AND MAIN RESULTS: It was found that administration of AM 281 could prevent the hemodynamic changes induced by sepsis. Reflex responses, including the pinna, corneal, paw or tail flexion, and righting reflexes, and the escape response significantly decreased in the CLP and CLP + L-N6-(1-iminoethyl)-lysine groups at 48 hrs after the surgery. In contrast, no changes in these reflex responses were found between the CLP + AM 281 and control and sham groups. In addition, no effects of the administration of AM 281 on neurologic function and mortality rate in the control group were found. Tissue caspase-3 levels were elevated at 48 hrs after CLP in the CLP alone group (means +/- sd: control, 3.9 +/- 0.4; sham, 4.2 +/- 0.4; CLP, 7.1 +/- 1.0 [p < .01]; CLP + AM 281, 4.0 +/- 0.5 densitometric units). In addition, administration of AM 281 also decreased the mortality rate (p < .05).
CONCLUSIONS: Administration of AM 281 prevented the hemodynamic changes and development of neurologic dysfunction occurring in association with septic shock, and could decrease the mortality rate in experimentally induced septic shock in rats. Although further studies are necessary to determine whether endogenous cannabinoids cause septic encephalopathy in rats directly or via their effects on systemic hemodynamics, the beneficial effects of AM 281 on these rats might have significant therapeutic implications in cases of septic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16276190     DOI: 10.1097/01.ccm.0000187010.14426.cc

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

Review 1.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

2.  Contributions of TRPV1, endovanilloids, and endoplasmic reticulum stress in lung cell death in vitro and lung injury.

Authors:  Karen C Thomas; Jessica K Roberts; Cassandra E Deering-Rice; Erin G Romero; Randal O Dull; Jeewoo Lee; Garold S Yost; Christopher A Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-23       Impact factor: 5.464

3.  Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; György Haskó; Lucas Liaudet; Ken Mackie; Pál Pacher
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation.

Authors:  Tomoharu Shimizu; Kazuyoshi Hanasawa; Koichi Sato; Masahiko Umeki; Nobuhiko Koga; Tatsushi Naganuma; Seiji Sato; Tomonori Shimonishi; Toshiaki Ikeda; Naoto Matsuno; Satoshi Ono; Hitoshi Saitoh; Koshi Satoh; Yoshimasa Otani; Yoshihiro Endo; Yutaka Eguchi; Tohru Tani
Journal:  Langenbecks Arch Surg       Date:  2008-08-07       Impact factor: 3.445

6.  The cannabinoid receptor 2 is critical for the host response to sepsis.

Authors:  Johannes Tschöp; Kevin R Kasten; Ruben Nogueiras; Holly S Goetzman; Cynthia M Cave; Lisa G England; Jonathan Dattilo; Alex B Lentsch; Matthias H Tschöp; Charles C Caldwell
Journal:  J Immunol       Date:  2009-06-12       Impact factor: 5.422

7.  Cannabinoid receptor 2 protects against acute experimental sepsis in mice.

Authors:  Huan Gui; Yang Sun; Zhu-Min Luo; Ding-Feng Su; Sheng-Ming Dai; Xia Liu
Journal:  Mediators Inflamm       Date:  2013-05-28       Impact factor: 4.711

8.  Reduced endothelium-dependent relaxation to anandamide in mesenteric arteries from young obese Zucker rats.

Authors:  Nubia S Lobato; Fernando P Filgueira; Roshini Prakash; Fernanda R Giachini; Adviye Ergul; Maria Helena C Carvalho; R Clinton Webb; Rita C Tostes; Zuleica B Fortes
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.